Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Cancer Discovery|January 10, 2015
JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic responseMaria Kleppe, Minsuk Kwak, Priya Koppikar, et al.
The Prostate|April 15, 2024
Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical modelsSumer Jasmine, Adel Mandl, Timothy E G Krueger, et al.
Blood Advances|February 27, 2026
Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemiaHarinder Gill, Francesca Palandri, David M Ross, et al.
Blood|October 8, 2015
Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemiasNicole Kucine, Sachie Marubayashi, Neha Bhagwat, et al.
Cancer Cell|December 19, 2017
Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative NeoplasmsMaria Kleppe, Richard Koche, Lihua Zou, et al.
Cancer Cell|June 14, 2011
Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemiaThomas Schmidt, Behzad Kharabi Masouleh, Sonja Loges, et al.
Cancer Discovery|March 9, 2013
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemiaTakaomi Sanda, Jeffrey W Tyner, Alejandro Gutierrez, et al.
Blood|April 6, 2023
Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemiaQu Jiang, Johanna Stachelscheid, Johannes Bloehdorn, et al.
Blood|February 17, 2023
CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosisAndrew J Dunbar, Dongjoo Kim, Min Lu, et al.
Cancer Cell|July 16, 2015
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative NeoplasmsSara C Meyer, Matthew D Keller, Sophia Chiu, et al.
Pageof 4